Recent developments in cancer therapeutics have improved outcomes but have also been
associated with cardiovascular complications. Therapies harnessing the immune system …

… The treatment recommendations for immune-mediated necrotizing myopathy (IMNM) are
depicted here based on information in Allenbach et al. . In addition to corticosteroids and …

In an effort to find naturally occurring substances that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme
A reductase (HMGCR), statins were first discovered by Endo …

… Yves Allenbach opened the workshop with this first session, … Allenbach highlighted that
there is no increased risk of … Finally, Yves Allenbach compared clinical phenotypes of both anti-…

Abatacept for Nivolumab-Induced Myocarditis Autoimmune myocarditis is a rare but often
fatal complication of immune checkpoint inhibitor therapy for cancer. A case of glucocorticoid-…

Importance Idiopathic inflammatory myopathies are heterogeneous in their pathophysiologic
features and prognosis. The emergence of myositis-specific autoantibodies suggests that …

… Yves Allenbach et al. report that patients with necrotising auto-immune myopathies also
have an increased risk of malignancy, and that myositis-specific antibodies can be used to …

We describe a long-term observational study of a large cohort of patients with sporadic
inclusion body myositis and propose a sporadic inclusion body myositis weakness composite …

Necrotizing autoimmune myopathy (NAM) is a group of acquired myopathies characterized
by prominent myofiber necrosis with little or no muscle inflammation. Recently, researchers …

… Béhin and Y. Allenbach report no disclosures relevant to the manuscript. O. Benveniste is
a consultant/advisory board member for CSL Behring, Novartis, LFB, and Neovacs. …